AMRI has signed an agreement to acquire Prime European Therapeuticals S.p.A., also known as Euticals, for approximately $358 million. Euticals is a privately held company headquartered in Lodi, Italy, specializing in custom synthesis and the manufacture of active pharmaceutical ingredients (APIs). It operates a network of API facilities primarily in Italy, Germany, the U.S. and France. “The acquisition of Euticals will provide us an established custom synthesis presence in Europe and...